TrialAnnals of the rheumatic diseases2023

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.

Christopher T Ritchlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.